The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors

Journal of Bone and Mineral Research

Volumn 27, Issue 6, 2012, Pages 1322-1334

  Dani, Nadia ^a,b   Olivero, Martina ^a,b   Mareschi, Katia ^a,c   Van Duist, Marjan Maria ^a,b   Miretti, Silvia ^d   Cuvertino, Sara ^a,b   Patanè, Salvatore ^a,b   Calogero, Raffaele ^a   Ferracini, Riccardo ^e,f   Scotlandi, Katia ^g   Fagioli, Franca ^c   Di Renzo, Maria Flavia ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e Centre for Research and Medical Studies (CeRMS)   (Italy)

^f Centre for Research and Medical Studies ^*  (Italy)

^g RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

HEPATOCYTE GROWTH FACTOR RECEPTOR; MET ONCOGENE; OSTEO PROGENITOR; OSTEOSARCOMA; OSTEOSARCOMAGENESIS

Indexed keywords

SCATTER FACTOR RECEPTOR;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; CELL RENEWAL; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOMETRY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; NORMAL HUMAN; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL;

BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL LINEAGE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CLONE CELLS; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOSARCOMA; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84861325260     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1578     Document Type: Article

References (56)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF., Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4: 915-25.
2. Trusolino L, Comoglio PM., Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2002; 2: 289-300.
3. Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, Cremona O, Campanacci M, Comoglio PM., The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene. 1995; 10: 739-49.
4. Scotlandi K, Baldini N, Oliviero M, Di Renzo MF, Martano M, Serra M, Manara MC, Comoglio PM, Ferracini R., Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol. 1996; 149: 1209-19.
5. Oda Y, Naka T, Takeshita M, Iwamoto Y, Tsuneyoshi M., Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol. 2000; 31: 709-16.
6. Wallenius V, Hisaoka M, Helou K, Levan G, Mandahl N, Meis-Kindblom JM, Kindblom LG, Jansson JO., Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am J Pathol. 2000; 156: 821-9.
7. MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, Tsan R, Thamm DH, Radinsky R., c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis. 2003; 20: 421-30.
8. Federman N, Bernthal N, Eilber FC, Tap WD., The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol. 2009; 10: 82-93.
9. Helman LJ, Meltzer P., Mechanisms of sarcoma development. Nat Rev Cancer. 2003; 3: 685-94.
10. Clark JC, Dass CR, Choong PF., A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008; 134: 281-97.
11. Kansara M, Thomas DM., Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007; 26: 1-18.
12. Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, Rodda SJ, Snay E, Dunning P, Fahey FH, Alt FW, McMahon AP, Orkin SH., Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008; 22: 1662-76.
13. Levings PP, McGarry SV, Currie TP, Nickerson DM, McClellan S, Ghivizzani SC, Steindler DA, Gibbs CP., Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res. 2009; 69: 5648-55.
14. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PC., Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009; 219: 294-305.
15. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR, Iwakuma T., CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer. 2010; 70: 4602-12.
16. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, Pirozzi G, Papaccio G., Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 2011; 25: 2022-30.
17. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, Suva D, Clement V, Provero P, Cironi L, Osterheld MC, Guillou L, Stamenkovic I., Identification of cancer stem cells in Ewing's sarcoma. Cancer Res. 2009; 69: 1776-81.
18. Charbord P., Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther. 2010; 21: 1045-56.
19. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K, Cironi L, Janiszewska M, Petricevic T, Suva D, Tercier S, Joseph JM, Guillou L, Stamenkovic I., EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes. 2010; 24: 916-32.
20. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O., Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007; 11: 421-9.
21. Reya T, Morrison SJ, Clarke MF, Weissman IL., Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105-11.
22. Passegue E, Weisman IL., Leukemic stem cells: where do they come from?. Stem Cell Rev. 2005; 1: 181-8.
23. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R, Chaudhury S, Gilkes A, Knapper S, Beldjord K, Begum S, Rose S, Geddes N, Griffiths M, Standen G, Sternberg A, Cavenagh J, Hunter H, Bowen D, Killick S, Robinson L, Price A, Macintyre E, Virgo P, Burnett A, Craddock C, Enver T, Jacobsen SE, Porcher C, Vyas P., Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011; 19: 138-52.
24. Ailles LE, Weissman IL., Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007; 18: 460-6.
25. Mohseny AB, Hogendoorn PC., Mesenchymal tumors: when stem cells go mad. Stem Cells. 2011; 29: 397-403.
26. Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF., MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 2006; 66: 4750-7.
27. Sottile V, Halleux C, Bassilana F, Keller H, Seuwen K., Stem cell characteristics of human trabecular bone-derived cells. Bone. 2002; 30: 699-704.
28. Mareschi K, Ferrero I, Rustichelli D, Aschero S, Gammaitoni L, Aglietta M, Madon E, Fagioli F., Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem. 2006; 97: 744-54.
29. Mareschi K, Novara M, Rustichelli D, Ferrero I, Guido D, Carbone E, Medico E, Madon E, Vercelli A, Fagioli F., Neural differentiation of human mesenchymal stem cells: Evidence for expression of neural markers and eag K+ channel types. Exp Hematol. 2006; 34: 1563-72.
30. Gibbs CP, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA., Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 2005; 7 (11): 967-76.
31. Ferracini R, Scotlandi K, Cagliero E, Acquarone F, Olivero M, Wunder J, Baldini N., The expression of Met/hepatocyte growth factor receptor gene in giant cell tumors of bone and other benign musculoskeletal tumors. J Cell Physiol. 2000; 184: 191-6.
32. Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi S, Serra M, Astolfi A, Bertoni F, Alami J, Yeger H, Picci P, Scotlandi K., The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol. 2002; 160: 849-59.
33. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C., Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer. 2010; 49: 40-51.
34. Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, Llombart-Bosch A, Cleton-Jansen AM., Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest. 2011; 91: 1195-205.
35. Tuli R, Seghatoleslami MR, Tuli S, Wang ML, Hozack WJ, Manner PA, Danielson KG, Tuan RS., A simple, high-yield method for obtaining multipotential mesenchymal progenitor cells from trabecular bone. Mol Biotechnol. 2003; 23: 37-49.
36. Calo E, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA., Rb regulates fate choice and lineage commitment in vivo. Nature. 2010; 466: 1110-4.
37. Billiard J, Moran RA, Whitley MZ, Chatterjee-Kishore M, Gillis K, Brown EL, Komm BS, Bodine PV., Transcriptional profiling of human osteoblast differentiation. J Cell Biochem. 2003; 89: 389-400.
38. Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F, Prokesch A, Paar C, Scheideler M, Windhager R, Preisegger KH, Trajanoski Z., Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation. BMC Genomics. 2007; 8: 70.
39. Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ, Journe F., The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer. 2010; 10: 298.
40. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR., Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284: 143-7.
41. Dezawa M, Kanno H, Hoshino M, Cho H, Matsumoto N, Itokazu Y, Tajima N, Yamada H, Sawada H, Ishikawa H, Mimura T, Kitada M, Suzuki Y, Ide C., Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest. 2004; 113: 1701-10.
42. Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, Lee SH, Gaudio E, Zanesi N, Jones KB, DeYoung B, Amir G, Gebhardt M, Warman M, Stein GS, Stein JL, Lian JB, Aqeilan RI., Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res. 2010; 70: 5577-86.
43. Kawasaki T, Niki Y, Miyamoto T, Horiuchi K, Matsumoto M, Aizawa M, Toyama Y., The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation. Biomaterials. 2010; 31: 1191-8.
44. Blanquaert F, Delany AM, Canalis E., Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts. Endocrinology. 1999; 140: 1069-74.
45. Amano O, Koshimizu U, Nakamura T, Iseki S., Enhancement by hepatocyte growth factor of bone and cartilage formation during embryonic mouse mandibular development in vitro. Arch Oral Biol. 1999; 44: 935-46.
46. Comoglio PM, Giordano S, Trusolino L., Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008; 7: 504-16.
47. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM., Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009; 15: 2207-14.
48. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ., Efficient tumour formation by single human melanoma cells. Nature. 2008; 456: 593-8.
49. Veselska R, Hermanova M, Loja T, Chlapek P, Zambo I, Vesely K, Zitterbart K, Sterba J., Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines. BMC Cancer. 2008; 8: 300.
50. Eames BF, Sharpe PT, Helms JA., Hierarchy revealed in the specification of three skeletal fates by Sox9 and Runx2. Dev Biol. 2004; 274: 188-200.
51. Delorme B, Ringe J, Pontikoglou C, Gaillard J, Langonne A, Sensebe L, Noel D, Jorgensen C, Haupl T, Charbord P., Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells. 2009; 27: 1142-51.
52. Hopyan S, Gokgoz N, Bell RS, Andrulis IL, Alman BA, Wunder JS., Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours. J Orthop Res. 1999; 17: 633-8.
53. Choi J, Curtis SJ, Roy DM, Flesken-Nikitin A, Nikitin AY., Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency. Am J Pathol. 2010; 177: 2645-58.
54. Berman SD, Calo E, Landman AS, Danielian PS, Miller ES, West JC, Fonhoue BD, Caron A, Bronson R, Bouxsein ML, Mukherjee S, Lees JA., Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA. 2008; 105: 11851-6.
55. Grano M, Galimi F, Zambonin G, Colucci S, Cottone E, Zallone AZ, Comoglio PM., Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA. 1996; 93: 7644-8.
56. Gorlick R., Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 2009; 152: 467-78.